#4-78E. Frontiers in Allergy and Immunology: Highlights from the 2025 CIA Symposium (JACI, 2026)

Are you curious about the next wave of therapeutic strategies for refractory allergic and immunologic diseases? In this episode, we dive into the "Highlights from the 2025 Symposium of the Collegium Internationale Allergologicum," a comprehensive overview of the latest advancements in the field. This article expertly summarizes cutting-edge insights into allergic pathogenesis, exploring the non-IgE-mediated functions of mast cells, complex immunometabolism pathways, and the nuanced roles of the gut microbiome1more_horiz. The most groundbreaking clinical takeaway is the promising potential of next-generation treatments, specifically highlighting Bruton's tyrosine kinase (BTK) inhibitors for acute anaphylaxis and novel bispecific antibodies targeting multiple pathways56. This is exceptionally important for physician listeners, as it provides a valuable opportunity to anticipate near-future clinical practices and incoming paradigm shifts in allergy management7. However, a critical caveat to consider is that this summary includes unpublished conference reports; therefore, clinicians must remain vigilant and await fully peer-reviewed evidence before altering established practices1. By exploring these frontiers, you can actively prepare for the future of patient care.

Citation: Bieber T, Vercelli D, et al. Highlights from the 2025 Symposium of the Collegium Internationale Allergologicum. The Journal of Allergy and Clinical Immunology. 2026. DOI: https://doi.org/10.1016/j.jaci.2026.05.028

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.